Opthea To Receive Funding Driven By Potential Of Sozinibercept
Opthea Limited (OPT) said it expects to receive the remaining $35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth. Also, the company has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional $50 million in funding.